Related references
Note: Only part of the references are listed.
Review
Biochemistry & Molecular Biology
Padmanee Sharma et al.
Summary: Immune checkpoint therapy (ICT) has significantly improved clinical outcomes and provided long-lasting benefits, including potential cure, for cancer patients. However, there are varying response rates and the need for predictive biomarkers to optimize patient selection. This review explores the underlying biology of anti-tumor immune response and resistance to ICT, discusses current challenges, and outlines strategies for subsequent clinical trials and combination therapies with ICT.
Review
Oncology
Matteo Santoni et al.
Summary: In the MOUSEION-03 study, a meta-analysis was conducted to determine the possibility of achieving complete remissions (CR) with immunotherapy or immuno-oncology combinations in cancer patients. The results showed that the use of immunotherapy can significantly increase the chance of achieving complete remission in cancer patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Alessandro Di Federico et al.
Summary: This article discusses the main evidence regarding the use of Y-90-TARE in HCC, the recent progress of immunotherapy in this tumor, and the preclinical rationale of combining VEGF blockade with the other two treatment strategies. HCC has an extremely heterogeneous tumor immune microenvironment. Combining an immune-checkpoint inhibitor with VEGF blockade and Y-90-TARE might overcome primary resistances observed when each of these treatments is administered alone.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)
Article
Geriatrics & Gerontology
Zhelong Liu et al.
Summary: The study demonstrates that omeprazole can ameliorate cancer cachexia by inhibiting the release of Hsp70 and Hsp90 from cancer cells. Experimental evidence in mice showed that omeprazole treatment could prevent muscle wasting and increase survival rate.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Review
Chemistry, Medicinal
Lei Wang et al.
Summary: Heat shock protein 90 (HSP90) is crucial in cancer cells, but its inhibitors have limited efficacy and side effects. Researchers are investigating the disruption of the HSP90-CDC37-kinase complex as an alternative solution to avoid limitations.
MEDICINAL RESEARCH REVIEWS
(2022)
Review
Gastroenterology & Hepatology
Alessandro Rizzo et al.
Summary: This article discusses the available evidence regarding predictive biomarkers of response to immunotherapy in hepatocellular carcinoma (HCC) patients, highlighting the need for further research on biochemical predictors of response to immune checkpoint inhibitors (ICIs) in HCC.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Oncology
Alessandro Rizzo et al.
Summary: The meta-analysis points out that PPIs and H2RAs could impact ICIs efficacy in NSCLC patients, emphasizing the urgent need to understand the factors affecting treatment response or resistance.
Article
Multidisciplinary Sciences
Scott A. Scarneo et al.
Summary: Hsp90 has been investigated as a therapeutic target in cancer for over two decades. The membrane expressed form of Hsp90 (mHsp90) plays a crucial role in T cell activation and could be a therapeutic target for chronic diseases like rheumatoid arthritis.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Zarema Albakova et al.
Summary: The HSP90 family plays an important role in tumor growth and development, and further exploration is needed to understand its involvement in tumor immunology and cancer immunotherapy. In some lymphoma patients, different expressions of HSP90 are related to immune cell functions.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
David Y. Oh et al.
Summary: Cytotoxic CD4(+) T cells play important roles in both cancer and non-cancer environments, where they can directly kill cancer cells. They are also found in situations like infection and autoimmunity. The cytolytic mechanisms of cytotoxic CD4(+) T cells vary across different disease states.
Review
Cell Biology
Jie Gao et al.
Summary: T cells play a crucial role in antitumor immunity, with their numbers and function regulated by nutrient uptake and utilization. Targeting T cell metabolism is a new therapeutic strategy that can enhance the efficacy of immunotherapy.
JOURNAL OF LEUKOCYTE BIOLOGY
(2021)
Article
Chemistry, Medicinal
Aotong Zhang et al.
Summary: PNSA has inhibitory effects on adhesion, migration, and invasion of TNBC and Trastuzumab-resistant cells, reversing EMT of MDA-MB-231 cells, and regulating the expression of various proteins through HSP90 inhibition. It also reduces the stability of EGFR and FGFR proteins, decreases PD-L1 expression, and enhances NK cell-mediated killing of breast cancer cells, showing its potential as an anti-metastasis agent.
Article
Multidisciplinary Sciences
Liangtao Zheng et al.
Summary: This study constructed a pan-cancer atlas of T cells across 21 cancer types, revealing different composition patterns and state-transition paths of T cells. The correlation between certain T cell populations and patient characteristics sheds light on possible determinants of the tumor microenvironment, providing new insights into T cell immunity and precision immunotherapy.
Review
Pharmacology & Pharmacy
Monimoy Banerjee et al.
Summary: Hsp90 is a molecular chaperone essential for the maturation of diverse client proteins, some of which are cancer targets. Inhibiting Hsp90 activity offers potential for drug development in treating diseases such as cancer. Various assays and technologies are being used to find specific and potent Hsp90-targeting drugs.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Microbiology
Sue Wickner et al.
Summary: Heat shock protein 90 (Hsp90) is a molecular chaperone that folds and remodels proteins, regulating the activity of substrate proteins. Bacterial Hsp90 collaborates with Hsp70 and its cochaperones for protein remodeling, while eukaryotic Hsp90 involves over 20 cochaperones in addition to Hsp70. Further exploration of the bacterial chaperone system may provide insights into the complex eukaryotic Hsp90 system.
ANNUAL REVIEW OF MICROBIOLOGY, VOL 75, 2021
(2021)
Article
Oncology
Nikola Cousin et al.
Summary: A new study using a lymphatic-specific PD-L1 knockout mouse model reveals that lymphatic endothelial PD-L1 expression reduces tumor immunity by inducing apoptosis in tumor-specific CD8(+) central memory cells in tumor-draining lymph nodes.
Article
Biochemistry & Molecular Biology
Yufan Qiu et al.
Summary: The study reveals that PD-1 can be secreted in an exosomal form by activated T cells and interact remotely with PD-L1. This interaction can attenuate the suppression of tumor-specific cytotoxic T cell activity by PD-L1, restoring tumor surveillance.
Review
Immunology
Fatima Ferragut et al.
Summary: The immune response of CD4(+) and CD8(+) T cells against T. cruzi is crucial for parasite control and disease pathogenesis. Despite the identification of some T cell epitopes, further research is needed to delve deeper into the specific targets of T cell memory response.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Adam P. Curnock et al.
Summary: The study developed PD-1 agonist ImmTAAI molecules that can inhibit T cell function by mimicking the action of PD-L1. These molecules specifically bind to target cells and effectively activate the PD-1 receptor on interacting T cells, achieving immune suppression.
Review
Biotechnology & Applied Microbiology
Julia L. Crunden et al.
Summary: Hsp90 is a central regulator of cellular proteostasis, playing a key role in stabilizing essential proteins and controlling genetic variation release. Research on the tools and techniques for mapping Hsp90 networks in fungal species is crucial for understanding protein interaction networks and evolutionary history.
FEMS YEAST RESEARCH
(2021)
Review
Immunology
Jack D. Chan et al.
Summary: The differentiation status of tumor-specific T cells greatly impacts their anti-tumor activity, with less differentiated T cells showing better therapeutic effects due to their enhanced expansion and long-term persistence. Adoptive transfer of T cells with stem-like memory or precursor phenotype is associated with improved therapeutic outcomes in cancer patients. Advances in understanding T cell differentiation at the epigenetic and transcriptional levels have led to the development of novel methods for generating more persistent and functional tumor-specific T cells.
NATURE REVIEWS IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Keisuke Yamamoto et al.
Article
Pharmacology & Pharmacy
Jiajia Dai et al.
BIOCHEMICAL PHARMACOLOGY
(2020)
Article
Oncology
Tae-Min Cho et al.
Article
Multidisciplinary Sciences
Timothy J. Haggerty et al.
Article
Biochemical Research Methods
Timothy J. Haggerty et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
(2012)
Article
Oncology
Len Neckers et al.
CLINICAL CANCER RESEARCH
(2012)
Article
Immunology
Theodore J. Yun et al.
JOURNAL OF IMMUNOLOGY
(2011)
Review
Oncology
J. E. Bohonowych et al.
JOURNAL OF ONCOLOGY
(2010)
Article
Biotechnology & Applied Microbiology
Chi-Chen Lin et al.
Article
Multidisciplinary Sciences
MMU Ali et al.
